Argenx Se (ARGX) Cash & Equivalents (2015 - 2026)
Argenx Se's (ARGX) quarterly Cash & Equivalents came in at $3.6 billion in Q2 2026, up 71.81% YoY from $2.1 billion in Q2 2025, and up 2.66% on a QoQ basis from $3.5 billion in Q4 2025.
Argenx Se (ARGX) Cash & Equivalents (2015 - 2026) Analysis & Trends
Argenx Se (ARGX) has 12 years of Cash & Equivalents data on file, last reported at $3.6 billion in Q2 2026.
- Quarterly Cash & Equivalents rose 71.81% year-over-year to $3.6 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.6 billion (up 71.81% YoY) and the FY2025 annual result came in at $3.5 billion, up 132.73% from the prior year.
- Cash & Equivalents climbed to $3.6 billion in Q2 2026, from $3.5 billion in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $3.6 billion in Q2 2026 to a low of $800.7 million in Q4 2022.
- A 5-year average of $1.9 billion and a median of $1.5 billion in 2024 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2022 — Cash & Equivalents slumped 40.0% — and 2023, when it jumped 155.87%.
- Tracing ARGX's Cash & Equivalents over 5 years: stood at $800.7 million in 2022, then jumped by 155.87% to $2.0 billion in 2023, then dropped by 26.79% to $1.5 billion in 2024, then soared by 132.73% to $3.5 billion in 2025, then advanced by 2.66% to $3.6 billion in 2026.
- The last three Cash & Equivalents figures came in at $3.6 billion (Q2 2026), $3.5 billion (Q4 2025), and $2.1 billion (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 1.25 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.58 Bn |
| Dec 31, 2025 | 3.49 Bn |
| Jun 30, 2025 | 2.09 Bn |
| Dec 31, 2024 | 1.50 Bn |
| Jun 30, 2024 | 1.44 Bn |
| Dec 31, 2023 | 2.05 Bn |
| Jun 30, 2023 | 1.11 Bn |
| Dec 31, 2022 | 800.74 Mn |
| Jun 30, 2022 | 1.37 Bn |
| Dec 31, 2021 | 1.33 Bn |
| Jun 30, 2021 | 1.58 Bn |
| Dec 31, 2020 | 1.18 Bn |
| Jun 30, 2020 | 1.35 Bn |
| Dec 31, 2019 | 366.69 Mn |
| Jun 30, 2019 | 188.54 Mn |
| Dec 31, 2018 | 320.78 Mn |
| Jun 30, 2018 | 168.12 Mn |
| Dec 31, 2017 | 224.73 Mn |
| Jun 30, 2017 | 83.05 Mn |
| Dec 31, 2016 | 97.06 Mn |